The Cincinnati Research & Treatment Center team will be conducting research in San Diego at the Town and Country Resort from July 12-14th, 2022 before the 18th International Fragile X Conference for attendees.

Individuals with Fragile X syndrome are invited to participate.

Interested? Learn more below.

About the Study

Who can participate?

Individuals with Fragile X syndrome ages 6 months and older may be eligible to participate.

What will happen in the study?

Researchers at Cincinnati Children’s Hospital Medical Center want to partner with you or your child to learn more about Fragile X.

If the individual qualifies and decides to be in this research study, they may participate in study activities in San Diego at the Town and Country Resort from July 12-14th, 2022 before the 18th NFXF International Fragile X Conference.

Study activities may include computerized tasks, neurophysiological tasks (such as an EEG), cognitive assessments, parent interview and questionnaires.

What are the good things that can happen from this research?

Being in this study may not help you right now. This may help others with FXS later on.

What are the bad things that can happen from this research?

There are minimal risks involved in the study. However, we will take all necessary precautions to minimize this risk.

The completion of the other tasks may cause mild nervousness or fatigue (tiredness). EEG is a non-invasive way to measure brain activity that can be associated with sensory discomfort. Our staff is highly trained and will help minimize these risks.

There may be other risks that we do not know about yet.

Will I or my child be paid to complete this study?

Participants receive payment for participation depending on the items completed.

Travel support may be available for eligible families.

Who can I contact for more information?

If you are interested in participating in this research, you can complete the contact form below to send your information to the study team.

You can also email them at or call 513-803-1150.

Interested in Participating?

Our Most Recent Opportunities
If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.

Clinical Trial RECONNECT: ZYN002 Gel

This study will evaluate the efficacy and safety of ZYN002, a clear cannabidiol (CBD) gel that can be applied to the skin (called transdermal application) twice a day for the treatment of behavioral symptoms of Fragile X syndrome (FXS).